WBA - CVS Health Falls 24% in 3 Months: Should You Buy the Dip? | Benzinga
CVS Health (NYSE: CVS), the pharmacy retail and PBM powerhouse, has witnessed a substantial 24% decline over the past three months. In fact, during the last trading session, the stock closed at $56.62, which marked a more than 47% plunge from its 52-week high of $83.25 and was quite close to its 52-week low of $52.77.
Not only this, the stock is currently trading below its 50-day and 200-day moving averages, indicating the possibility of a further bearish shift in the stock's price.
CVS Below 50 & 200 Day SMA
Image Source: Zacks Investment Research
As the stock struggles to keep pace, it is now a big question for investors whether to get rid of CVS Health or grab a few more shares because the stock is hovering around its rock bottom. While the stock has been grappling with the industry-wide phenomenon of pharmacy reimbursement pressure, a turnaround might be in the cards, given its strategic initiatives that can change investors' perspectives in favor of CVS Health. Let us delve deeper.
What Pulled CVS Down?
Pharmacy Reimbursement Crisis: The entire retail pharmacy industry is currently grappling with continued pressure from non-reimbursable pharmacy expenses, which are significantly pulling down mass demand for prescription as well as over-the-counter drugs and vaccinations. Going by a National Association of Chain Drugs report, payors are substantially shrinking reimbursement, many times below the cost of buying and dispensing prescription drugs. This is putting substantial and unsustainable financial pressure on the companies to the extent that many of the industry players over the past year were seen either shutting down their entire business, reducing the number of stores or ...